AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
spectinomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, produced by Streptomyces strains | 2468 | 1695-77-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 7.50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 70 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 200.69 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 0.13 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.99 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.80 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK5,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK1,NTRK2,PDK2,PRKDC,TEK,ZAP70 | 21 | |||
| kinase-selectivity-class | CHUK,MAP2K6,PDK1 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 30, 1971 | FDA | PFIZER |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01XX04 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Other antibacterials |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
| CHEBI has role | CHEBI:76969 | bacterial metabolite |
Related Drugs by ATC class:
J01XX Other antibacterials 12 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Gonorrhea | indication | 15628003 | DOID:7551 |
| Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
| Acute gonococcal urethritis | indication | 29864006 | |
| Gonorrhea of rectum | indication | 42746002 | |
| Disseminated Gonococcal Infection | indication |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | Respiratory disease associated with Mannheimia haemolytica | Indication |
| Cattle | Respiratory disease associated with Pasteurella multocida | Indication |
| Cattle | Respiratory disease associated with Histophilus somni | Indication |
| Chickens | Infectious synovitis caused by Mycoplasma synoviae | Indication |
| Chickens | Prevention or control of losses caused by CRD associated with M gallisepticum (PPLO) | Indication |
| Dogs | Infectious diarrhea and gastroenteritis | Indication |
| Dogs | Infections caused by gram-negative and gram-positive organisms | Indication |
| Swine | Infectious bacterial enteritisassociated with Escherichia coli | Indication |
| Turkeys | Prevention of mortality associated with Arizona group infection | Indication |
| Turkeys | Chronic respiratory disease (CRD) associated with Escherichia coli | Indication |
| Turkeys | Control of airsacculitis associated with M meleagridis | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Spectinomycin Tablet and Injection | Zoetis Inc. | 1 |
| Spectam Scour Halt | Huvepharma EOOD | 1 |
| SpectoGard Water Soluble Powder | Bimeda Animal Health Limited | 1 |
| Spectam Injectable | Huvepharma EOOD | 1 |
| Spectinomycin Oral Liquid | Zoetis Inc. | 1 |
| L-S 50 Water Soluble Powder | Zoetis Inc. | 2 |
| Spectam Injectable | Elanco US Inc. | 1 |
| Spectam Tablets | Bimeda Animal Health Limited | 1 |
| Adspec Sterile Solution | Zoetis Inc. | 1 |
| PROSPEC Injectable, Spectinomycin Injectable | Zoetis Inc. | 1 |
| Lincomycin - Spectinomycin | Phibro Animal Health Corp. | 2 |
| Spectogard Scour-Chek | Bimeda Animal Health Limited | 1 |
| SpecLinx-50 | Bimeda Animal Health Limited | 2 |
| Lincomycin-Spectinomycin Water Soluble Powder | Huvepharma EOOD | 2 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.28 | acidic |
| pKa2 | 9.94 | Basic |
| pKa3 | 5.96 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 30S ribosomal protein S12 | Cytosolic other | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4018092 | VUID |
| N0000179731 | NUI |
| D08526 | KEGG_DRUG |
| 22189-32-8 | SECONDARY_CAS_RN |
| 4018092 | VANDF |
| 4019932 | VANDF |
| C0001268 | UMLSCUI |
| CHEBI:9215 | CHEBI |
| SCM | PDB_CHEM_ID |
| CHEMBL1167 | ChEMBL_ID |
| CHEMBL3989571 | ChEMBL_ID |
| DB00919 | DRUGBANK_ID |
| D000198 | MESH_DESCRIPTOR_UI |
| 15541 | PUBCHEM_CID |
| 11127 | IUPHAR_LIGAND_ID |
| 1429 | INN_ID |
| 93AKI1U6QF | UNII |
| 10862 | RXNORM |
| 4127 | MMSL |
| 5505 | MMSL |
| d00372 | MMSL |
| 002790 | NDDF |
| 004865 | NDDF |
| 24809001 | SNOMEDCT_US |
| 372882007 | SNOMEDCT_US |
| 86066003 | SNOMEDCT_US |
| 64058-48-6 | SECONDARY_CAS_RN |
Pharmaceutical products:
None